Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study

Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet. Haematology 2024-08, Vol.11 (8), p.e580-e592
Hauptverfasser: Locatelli, Franco, Antmen, Bulent, Kang, Hyoung Jin, Koh, Katsuyoshi, Takahashi, Yoshiyuki, Kupesiz, Alphan, Dias Matos, Maria Gabriela A, Chopra, Yogi, Bhat, Sunil, Im, Ho Joon, Güngör, Tayfun, Lu, Meng-Yao, Stefanelli, Tommaso, Rosko, Christine, St Pierre, Annie, Burock, Karin, Smith, Yvonne, Sinclair, Karen, Diaz-de-Heredia, Cristina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (ie,
ISSN:2352-3026
2352-3026
DOI:10.1016/S2352-3026(24)00174-1